BioSpace News Archive

Cardiac Insight, Inc. (“Cardiac Insight” or the “Company”) is a healthcare innovator specializing in wearable cardiac sensors and proprietary software that automatically analyzes electrocardiogram (ECG) data to improve early detection and diagnosis of cardiac arrythmias, such as atrial fibrillation (AFib).

Celon Pharma today announced filing for approval to start a Phase II clinical study of CPL’280, its second generation GPR40 agonist in type 2 diabetes.

Enanta Pharmaceuticals, Inc. today announced positive data from the first two dose cohorts of its Phase 1b study of EDP-514 in viremic chronic HBV patients who were not being treated with a nucleoside reverse transcriptase inhibitor (NUC).

Cyteir Therapeutics, Inc. today announced the closing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share.

Bioasis Technologies Inc. is pleased to announce that it has entered into a convertible security funding agreement dated June 22, 2021 with Lind Global Macro Fund, LP, an entity managed by The Lind Partners, a New York-based institutional investment management firm.

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share,